Login
Companies $NTLA
$9.97 +$0.11 (1.11%) After hours
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

intelliatx.com

What Do They Do?

Develops gene-editing drug candidates for patients with hereditary angioedema and transthyretin amyloidosis.

How Do They Make Money?

Partners pay Intellia through upfront license fees, research funding, shared-cost payments and development, regulatory and commercial milestones; it may also receive a share of sales of licensed products.

FY2025 revenue

Who Are Their Customers?

Revenue comes from collaboration partners such as Regeneron, which work with Intellia under licensing and research agreements.

Do Revenues Turn Into Profits?

No. It lost $412.7M in FY2025.

Operating income, FY2025
−652% of revenue
▲ +17% (Loss) vs FY2024 (−$534.3M, −923%)
Net income, FY2025
−610% of revenue
▲ +20% (Loss) vs FY2024 (−$519M, −897%)
Free cash flow, FY2025
−585% of revenue
▼ −12% (Loss) vs FY2024 (−$354.7M, −613%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −48%
vs $13.8M in Q3 FY2025
Net income
▼ −26% (Loss)
vs −$101.3M in Q3 FY2025
  • Sep 8, 2026 FDA accepts lonvo-z application for priority review The target action date is March 10, 2027, and FDA said it does not currently plan an advisory committee.

Growing. Revenue grew 2.0x in 4 years, from $33.1M in FY2021 to $67.7M in FY2025, about 20% a year.

Moving toward commercialization The older report describes a broad in vivo and ex vivo development pipeline; the latest report emphasizes launch preparation for lonvo-z and a U.S.-focused commercial and medical affairs team.

Who Do They Compete With?

Competes with ADARx Therapeutics, Argo Biopharmaceutical, BioCryst Pharmaceuticals, CSL, Gritgen Therapeutics, Ionis Pharmaceuticals, KalVista Pharmaceuticals, Pharming Group, Pharvaris, Takeda Pharmaceutical, Alnylam Pharmaceuticals, AstraZeneca Pharmaceuticals, BridgeBio Pharma, Bayer, Metagenomi Therapeutics, Novo Nordisk, Pfizer, and YolTech Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support